BioAtla, Inc. financial data

Symbol
BCAB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11085 Torreyana Road, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 390 % -37.7%
Debt-to-equity 94.4 % +156%
Return On Equity -187 % -110%
Return On Assets -96.3 % -47.8%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 48.3M shares +0.92%
Entity Public Float 91M USD +31.9%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 48.3M shares +1.05%
Weighted Average Number of Shares Outstanding, Diluted 48.3M shares +1.05%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 74.1M USD -28%
General and Administrative Expense 23.1M USD -13.7%
Operating Income (Loss) -86.2M USD +33.5%
Net Income (Loss) Attributable to Parent -81.8M USD +34.1%
Earnings Per Share, Basic -1.69 USD/shares +36.5%
Earnings Per Share, Diluted -1.69 USD/shares +36.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.5M USD -60%
Assets, Current 60.6M USD -58.9%
Property, Plant and Equipment, Net 906K USD -53.9%
Operating Lease, Right-of-Use Asset 763K USD -55.9%
Other Assets, Noncurrent 0 USD -100%
Assets 62.2M USD -58.9%
Accounts Payable, Current 2.93M USD -53.5%
Liabilities, Current 19.5M USD -45.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 39.3M USD -30.7%
Retained Earnings (Accumulated Deficit) -471M USD -21%
Stockholders' Equity Attributable to Parent 23M USD -75.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 23M USD -75.7%
Liabilities and Equity 62.2M USD -58.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.8M USD -36.1%
Net Cash Provided by (Used in) Financing Activities -13K USD +88.8%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 48.3M shares +0.92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.5M USD -60%
Deferred Tax Assets, Valuation Allowance 85.6M USD +51%
Deferred Tax Assets, Gross 86.2M USD +49.5%
Operating Lease, Liability 1.25M USD -56.1%
Lessee, Operating Lease, Liability, to be Paid 1.27M USD -56.8%
Property, Plant and Equipment, Gross 7.68M USD -6.14%
Operating Lease, Liability, Current 1.25M USD -21.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 845K USD -49.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 425K USD +3.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19K USD -79.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 845K USD -49.9%
Deferred Tax Assets, Operating Loss Carryforwards 25M USD +43.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 3.6M USD +83%
Lessee, Operating Lease, Liability, to be Paid, Year Four 845K USD 0%
Operating Lease, Payments 1.54M USD -5.48%
Additional Paid in Capital 494M USD +2.08%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 240K USD -18.1%
Deferred Tax Assets, Net of Valuation Allowance 545K USD -41.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%